Optimization of Drug Provision for Patients With Rheumatoid Arthritis Based on a Pharmacoeconomic Analysis in the Republic of Kazakhstan

Оптимизация лекарственного обеспечения пациентов, страдающих ревматоидным артритом, на основе применения фармакоэкономического анализа в Республике Казахстан
Zhakipbekov K.S. Serikbayeva E.A. Turgumbayeva A.A. Rakhymbayev N.A. Ashirov M.Z. Mironenkova Z.V. Umarov S.Z. Akpayeva K.M.
2025 Eco-Vector LLC

Vestnik Rossijskoj Voenno-Medicinskoj Akademii
2025 #27 Issue 4 477 - 484 pp.

BACKGROUND: Providing the least costly, safe, and highly effective pharmacotherapy to patients with rheumatoid arthritis remains an urgent issue. AIM: This work aimed to develop approaches for optimizing drug provision for patients with rheumatoid arthritis (using the city of Almaty as an example). METHODS: This work used the information resources of the Ministry of Health of the Republic of Kazakhstan; reports from the Almaty City Rheumatology Center, the State Register of Medicinal Products of the Republic of Kazakhstan, the Clinical Protocol for the Diagnosis and Treatment of Rheumatoid Arthritis No. 12 dated September 29, 2016; wholesale prices for medicinal products, antineoplastic agents, and immunomodulators (anatomical therapeutic chemical groups L01, L04) provided by the City Rheumatology Center; and statistical indicators accumulated based on data from the World Health Organization and the Bureau of National Statistics of the Agency for Strategic Planning and Reforms of the Republic of Kazakhstan. RESULTS: The highest disease prevalence (60%) was observed among working-age patients aged 35-55 years, whereas only 0.36% of the medicinal products used belonged to biologic agents. The cost ranking (ascending order) of adverse drug reaction therapy was as follows: adalimumab, etanercept, rituximab, tocilizumab, golimumab, and infliximab. With regard to additional cost expenditures, the leading agents (based on the lowest cost of the treatment course) were golimumab, rituximab, and infliximab. The lowest total treatment cost across all treatment stages (in ascending order) was identified for etanercept, adalimumab, and infliximab. CONCLUSION: Strengthening physician-led patient education regarding treatment strategies is necessary to improve adherence among patients with rheumatoid arthritis. To expand therapy options, the inclusion of etanercept in the guaranteed free medical care list must be considered. To reduce expenditures for medicinal provision, producing biologic agents in the Republic of Kazakhstan is required.

additional cost expenditures , biologic agents , cost of inpatient treatment , cost of therapy for adverse drug reactions , rheumatoid arthritis , sociological survey , total cost of illness

Text of the article Перейти на текст статьи

Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
Al-Farabi Kazakh National University, Almaty, Kazakhstan
Saint Petersburg State Chemical-Pharmaceutical University, Saint Petersburg, Russian Federation
Astana Medical University, Astana, Kazakhstan
Kirov Military Medical Academy, Saint Petersburg, Russian Federation

Asfendiyarov Kazakh National Medical University
Al-Farabi Kazakh National University
Saint Petersburg State Chemical-Pharmaceutical University
Astana Medical University
Kirov Military Medical Academy

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026